Geron Corporation Revenue and Competitors
Estimated Revenue & Valuation
- Geron Corporation's estimated annual revenue is currently $403k per year.
- Geron Corporation's estimated revenue per employee is $1,465
- Geron Corporation's total funding is $236.7M.
- Geron Corporation's current valuation is $386.3M. (January 2022)
- Geron Corporation has 275 Employees.
- Geron Corporation grew their employee count by 10% last year.
Geron Corporation Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Geron Corporation?
Geron Corporation is a development stage biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic products for applications in oncology and regenerative medicine, and research tools for drug discovery. The Company's product development programs are based upon three patented core technologies: telomerase, human embryonic stem cells and nuclear transfer. The Company is working to develop anti-cancer therapies based on telomerase inhibitors, oncolytic (cancer-killing) viruses and telomerase vaccines. The Company also intends to continue to develop and commercialize products using telomerase as a marker for cancer diagnosis, prognosis, patient monitoring and screening.keywords:N/A
Number of Employees
Employee Growth %
Geron Corporation News
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class...
Geron Corporation (NASDAQ:GERN) slumps 18% after hours after the firm has ... All of the securities in the offering are being sold by Geron.
By Colin Kellaher. Shares of Geron Corp. slid nearly 20% in premarket trading Wednesday after the biopharmaceutical company said it was...
The app is completely intuitive and convenient to use, removing any practical or logistical barriers to Adverse Event reporting. DUBLIN (PRWEB) January 26, 2021 Arriello, a global expert in pharmacovigilance consulting and life science outsourcing services, has today announced that Geron Corpo ...
Physicians injected the first-ever patient with millions of stem cells derived from human embryos in a clinical trial aimed at proving the treatment is safe for people with spinal cord injuries. The trial, sponsored by Geron Corp. (NSDQ:GERN), calls for patients to receive the injection within ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|